Instil Bio, Inc. Research and Development in Process
Instil Bio, Inc. (TIL) reported Research and Development in Process of $600.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-03-07
- Instil Bio, Inc. research and development in process for the quarter ending 2020-09-30 was $600.00K.
- Instil Bio, Inc. research and development in process for the quarter ending 2020-06-30 was $600.00K.
- Instil Bio, Inc. research and development in process for the quarter ending 2020-03-31 was $600.00K.
- Instil Bio, Inc. research and development in process for fiscal 2020 was $600.00K.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2020-12-31 | $600.00K 10-K · filed 2022-03-07 | |||
| 2020-09-30 | $600.00K 10-Q · filed 2021-11-15 | $1.20M derived: sum of 2 quarters · filed 2021-11-15 | $1.80M derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $600.00K 10-Q · filed 2021-08-12 | $1.20M derived: sum of 2 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $600.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |